hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06336694 id: SYSUFAH2021-025 briefTitle: A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic Adenocarcinoma overallStatus: COMPLETED date: 2021-01-01 date: 2022-10-31 date: 2023-07-30 date: 2024-03-29 date: 2024-03-29 name: First Affiliated Hospital, Sun Yat-Sen University class: OTHER briefSummary: Occult peritoneal metastases (OPM) in patients with pancreatic ductal adenocarcinoma (PDAC) are frequently overlooked during imaging. We aimed to develop and validate a CT-based deep learning-based radiomics (DLR) model with clinical-radiological characteristics to identify OPM in patients with PDAC before treatment. conditions: Pancreatic Neoplasms studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 302 type: ACTUAL name: surgery or diagnostic staging laparoscopy measure: diagnosed with peritoneal metastases sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shi Siya city: Guangzhou state: Guangdong zip: 510000 country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06336681 id: #12966 briefTitle: Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB) acronym: IMT_EIB overallStatus: RECRUITING date: 2022-02-10 date: 2025-08 date: 2025-08 date: 2024-03-29 date: 2024-03-29 name: Indiana University class: OTHER briefSummary: Due to the lack of studies examining the impact of inspiratory muscle training (IMT) on the severity of exercise-induced bronchoconstriction (EIB) and exercise performance, the specific aim of this study is to assess the efficacy of flow-resistive IMT on EIB severity and symptoms, short-acting beta-2-agonist medication use, operating lung volumes, respiratory and limb locomotor muscle deoxygenation during constant-load cycling exercise, exertional dyspnea, and cycling time-trial performance. conditions: Exercise Induced Bronchospasm conditions: Exercise Induced Asthma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: PrO2Fit Device measure: Exercise-Induced Bronchoconstriction (EIB) Severity measure: Maximum Inspiratory Pressure and Sustained Maximum Inspiratory Pressure measure: 16-km Cycling Time-Trial Time to Completion measure: 16-km Cycling Time-Trial Power Output measure: Constant Load Performance measure: Perception of Breathing Intensity and Unpleasantness and Leg Fatigue measure: Deoxygenation of the respiratory and limb locomotor muscles by near-infrared spectroscopy measure: Femoral blood flow (FBF) of the limb locomotor muscles by ultrasound measure: Lung Volumes sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: School of Public Health-Bloomington status: RECRUITING city: Bloomington state: Indiana zip: 47405 country: United States name: Tim Mickleborough, Ph.D. role: CONTACT phone: 812-855-0753 email: tmickleb@indiana.edu lat: 39.16533 lon: -86.52639 hasResults: False
nctId: NCT06336668 id: REB23-1283 briefTitle: Source of Human Milk Fortifier and Intestinal Oxygenation in Preterm Infants <30 Weeks Gestation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-02-28 date: 2026-02-28 date: 2024-03-29 date: 2024-04-01 name: University of Calgary class: OTHER briefSummary: Preterm infants require higher nutritional intakes during the neonatal phase than they do at any other stage of their development. Standard volumes of human milk alone do not offer sufficient nourishment to these infants. There are multiple options for fortifying human milk, which vary depending on whether the fortifier is derived from bovine sources (B-HMF) or human sources (H-HMF). Fortifying human milk has been proven to enhance growth in preterm infants without raising the risk of necrotizing enterocolitis (NEC), though it could potentially affect feeding tolerance. Changes in blood flow and oxygen levels in the intestines are commonly observed in infants experiencing feeding intolerance. Research indicates that feeding a mother's own milk (MOM) doesn't affect splanchnic (intestinal) oxygenation, whereas it decreases when feeding bovine-derived human milk fortifiers (B-HMF) or preterm formula, indicating greater oxygen requirements in the intestines of preterm infants fed these alternatives.
The goal of this clinical trial is to compare the effect of H-HMF and B-HMF on splanchnic oxygenation in infants less than 30 weeks. conditions: Feeding; Difficult, Newborn studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Prospective randomized-controlled crossover trial comparing 2 different HMFs and 2 intestinal rSO2S periods in random order: 6 hours while on B-HMF and 6 hours on H-HMF with at least 6 hours washing period primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Randomizing the participants to either Bovine-HMF or Human Milk based-HMF will mask the Investigator whoMasked: INVESTIGATOR count: 18 type: ESTIMATED name: Human milk-based HMF measure: Change in Splanchnic regional oxygenation(rSO2S) measured by Near Infrared Spectroscopy measure: Changes in SMA doppler peak flow velocity (PSV) measure: Changes in SMA doppler end-diastolic velocity (EDV) measure: Changes in SMA doppler Porcelout's resistance index (RI) sex: ALL maximumAge: 30 Weeks stdAges: CHILD hasResults: False
nctId: NCT06336655 id: 153309 briefTitle: Physiology of Unloading VA ECMO Trial overallStatus: RECRUITING date: 2024-04-15 date: 2028-02-01 date: 2029-02-01 date: 2024-03-29 date: 2024-04-25 name: University of Utah class: OTHER name: University of Minnesota briefSummary: The goal of this clinical trial is to compare the use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) with and without left ventricular (LV) unloading in patients being treated for non-postoperative cardiogenic shock (CS). The main aims of the study are:
Participants who are being treated with VA ECMO will be randomized to receive or not receive LV unloading in the form of an intra-aortic balloon pump (IABP). Over the course of the study, the investigators will obtain measurements via lab work, echocardiography, and pulmonary artery catheter that will allow comparison of the two groups. conditions: Cardiogenic Shock studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 104 type: ESTIMATED name: IABP measure: Change in pulmonary capillary wedge pressure measure: Change in pulmonary artery diastolic pressure measure: Change in left ventricular end diastolic diameter measure: Change in N-terminal pro b-type natriuretic peptide measure: Hemodynamic stability measure: Global cardiovascular function measure: Difference in partial pressure of carbon dioxide (pCO2) measure: Lactate measure: Cardiac BIN1 measure: Troponin I measure: Tumor necrosis factor alpha measure: Ejection fraction percentage measure: Interferon gamma measure: Limb ischemia measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Utah status: RECRUITING city: Salt Lake City state: Utah zip: 84132 country: United States name: Joseph E. Tonna, MD, FAAEM role: CONTACT phone: 801-587-9373 email: joseph.tonna@hsc.utah.edu lat: 40.76078 lon: -111.89105 hasResults: False
nctId: NCT06336642 id: 2023-0933 id: NCI-2024-02452 type: OTHER domain: NCI-CTRP Clinical Trials Registry briefTitle: Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology overallStatus: NOT_YET_RECRUITING date: 2024-09-30 date: 2030-03-31 date: 2032-03-31 date: 2024-03-29 date: 2024-03-29 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn about the effect of Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON) treatment on the severity of shortness of breath in patients with cancer. conditions: Dyspnea studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 150 type: ESTIMATED name: SPOT-ON Early Start name: SPOT-ON Delayed Start measure: Primary Outcome Measure: 1.Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: David Hui, MD role: CONTACT phone: 713-792-6258 email: dhui@mdanderson.org lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06336629 id: WIN2023 briefTitle: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-15 date: 2024-10 date: 2024-10 date: 2024-03-29 date: 2024-03-29 name: Sun Pharmaceutical Industries Limited class: INDUSTRY briefSummary: Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice. conditions: Acne Vulgaris studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Winlevi (clascoterone) 1% & Duac gel measure: The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16. measure: Percent of total lesion reduction at week 16 compared to baseline measure: Percent of inflammatory lesion reduction at week 16 compared to baseline measure: Percent of non-inflammatory lesion reduction at week 16 compared to baseline. measure: Tolerability measures of erythema based on 5-point severity scale measure: Tolerability measures of dryness based on 5-point severity scale measure: Tolerability measures of peeling based on 5-point severity scale measure: Assessment of skin oiliness based on 5-point severity scale measure: Tolerability measures of burning/stinging based on 6-point severity scale measure: Tolerability measures of pruritus based on 6-point severity scale sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Skin Sciences, PLLC city: Louisville state: Kentucky zip: 40217 country: United States lat: 38.25424 lon: -85.75941 hasResults: False
nctId: NCT06336616 id: 31164 briefTitle: Getting Out of the House: Using Behavioral Activation to Increase Community Participation overallStatus: RECRUITING date: 2024-02-15 date: 2026-08 date: 2026-12 date: 2024-03-29 date: 2024-04-10 name: Temple University class: OTHER name: National Institute on Disability, Independent Living, and Rehabilitation Research briefSummary: The goal of this study is to evaluate the effectiveness of an behavioral activation intervention to increase meaningful activity and community participation for people with serious mental illness.
The study will enroll 52 participants split into 4 cohorts of 13. The study will use a multiple baseline design and, as such, all participants will receive the intervention and there is no control group. conditions: Major Depressive Disorder conditions: Schizo Affective Disorder conditions: Schizophrenia conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SEQUENTIAL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 52 type: ESTIMATED name: Behavior Activation measure: Activity Logs measure: Participation Checklist measure: Behavior Activation for Depression Scale measure: Temple University Community Participation Measure measure: Community Mobility (Global Positioning System; GPS) measure: Community Mobility (Global Positioning System; GPS) measure: Lerman Quality of Life Interview measure: New General Self-Efficacy Scale (adapted to participation) measure: Recovery Assessment Scale (RAS) measure: Activity Assessment Scale measure: Capabilities and Opportunities for Participation Questionnaire measure: Self-Control and Self-Management Scale measure: Habit Strength Scale measure: University of California Los Angeles Loneliness Scale measure: Lehman Quality of LIfe (QOL) Interview Social Relations sub scale measure: Hopkins Symptoms Checklist measure: The Life Engagement Test measure: The University of Rhode Island Change Assessment Measure (URICA) measure: Reward Probability Index sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Temple University status: RECRUITING city: Philadelphia state: Pennsylvania zip: 19120 country: United States name: Crystal Slanzi role: CONTACT lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06336603 id: WIN2022 briefTitle: A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-15 date: 2024-09 date: 2024-09 date: 2024-03-29 date: 2024-03-29 name: Sun Pharmaceutical Industries Limited class: INDUSTRY briefSummary: Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice. conditions: Acne Vulgaris studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Winlevi (clascoterone) 1% & Adapalene 0.3% gel measure: The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16. measure: Percent of total lesion reduction at week 16 compared to baseline measure: Percent of inflammatory lesion reduction at week 16 compared to baseline measure: Percent of non-inflammatory lesion reduction at week 16 compared to baseline measure: Tolerability measures of erythema based on 5-point severity scale measure: Tolerability measures of dryness based on 5-point severity scale measure: Tolerability measures of peeling based on 5-point severity scale measure: Assessment of skin oiliness based on 5-point severity scale measure: Tolerability measures of burning/stinging based on 6-point severity scale measure: Tolerability measures of pruritus based on 6-point severity scale sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Skin Sciences, PLLC city: Louisville state: Kentucky zip: 40217 country: United States lat: 38.25424 lon: -85.75941 hasResults: False
nctId: NCT06336590 id: Pro2024000249 briefTitle: Student Exercise and Sleep Timing Study - Part 2 acronym: SiESTa 2 overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2026-12-01 date: 2026-12-16 date: 2024-03-29 date: 2024-03-29 name: Rutgers, The State University of New Jersey class: OTHER briefSummary: The purpose of this study is to examine the effects of a morning exercise intervention on sleep (quality and duration), mood (positive affect, anxiety, depression, anger), stress and productivity among undergraduate students (18-23 years) evening-exercisers with poor self-reported sleep quality.
Aim 3. Compared to the control condition, evening-exercisers prescribed morning exercise will exhibit decreased stress and increased productivity. conditions: Sleep conditions: Mood conditions: Stress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 62 type: ESTIMATED name: Morning Exercise measure: Sleep Quality measure: Mood measure: Stress measure: Productivity sex: ALL minimumAge: 18 Years maximumAge: 23 Years stdAges: ADULT facility: College Avenue Gym city: New Brunswick state: New Jersey zip: 08901 country: United States lat: 40.48622 lon: -74.45182 facility: Cook/Douglass Rec Center city: New Brunswick state: New Jersey zip: 08901 country: United States name: Assistant Director of Operations role: CONTACT phone: 848-932-8063 email: samantha.plum@rutgers.edu lat: 40.48622 lon: -74.45182 facility: Rutgers Fitness Center city: New Brunswick state: New Jersey zip: 08901 country: United States lat: 40.48622 lon: -74.45182 facility: Rutgers Sleep Lab city: New Brunswick state: New Jersey zip: 08901 country: United States lat: 40.48622 lon: -74.45182 facility: Livingston Rec Center city: Piscataway state: New Jersey zip: 08854 country: United States name: Assistant Director of Operations role: CONTACT phone: 848-932-8063 email: samantha.plum@rutgers.edu lat: 40.49927 lon: -74.39904 facility: Werblin Rec Center city: Piscataway state: New Jersey zip: 08854 country: United States name: Assistant Director of Operations role: CONTACT phone: 848-932-8063 email: samantha.plum@rutgers.edu lat: 40.49927 lon: -74.39904 hasResults: False
nctId: NCT06336577 id: 2024/0003 briefTitle: Infectious and Non-infectious Lower Respiratory Diseases in Children With Down Syndrome Followed in Pediatric Pulmonology Consultations in Ile-de-France acronym: ARBT21 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-03-29 name: Centre Hospitalier Sud Francilien class: OTHER briefSummary: The purpose of this study is to describe infectious and non-infectious lower respiratory tract diseases in children with Down syndrome followed in pediatric pulmonology consultations in Ile de France. conditions: Down Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 250 type: ESTIMATED name: lower respiratory tract disease measure: distribution of lower respiratory tract diseases sex: ALL minimumAge: 1 Day maximumAge: 17 Years stdAges: CHILD facility: Centre Hospitalier Sud Francilien city: Corbeil-Essonnes zip: 91106 country: France name: Yousra MESBAHI role: CONTACT phone: 0161697760 email: yousra.mesbahi@chsf.fr lat: 48.60603 lon: 2.48757 hasResults: False
nctId: NCT06336551 id: UniversityAmsterdam briefTitle: Acceptance and Commitment Therapy for Insomnia overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-01-26 date: 2026-01-26 date: 2024-03-28 date: 2024-03-29 name: University of Amsterdam class: OTHER briefSummary: Insomnia is a common sleep problem that impacts both physical and mental health. Acceptance and Commitment Therapy for Insomnia (ACT-I) is proposed as a promising new treatment for insomnia. However, its effectiveness without overlapping behavioral components of the current standard treatment, cognitive behavioral therapy, remains largely unknown.
* How do networks of insomnia symptoms or potential treatment processes (i.e., psychological (in)flexibility, sleep-related arousal, dysfunctional cognitions, and sleep-related safety behaviors) develop during and following ACT-I? conditions: Insomnia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Acceptance and Commitment Therapy for insomnia (ACT-I) measure: Insomnia severity measure: Insomnia severity measure: Insomnia severity measure: Insomnia severity measure: General well-being measure: General well-being measure: General well-being measure: General well-being measure: Sleep-related quality of life measure: Sleep-related quality of life measure: Sleep-related quality of life measure: Sleep-related quality of life measure: Anxiety symptoms measure: Anxiety symptoms measure: Anxiety symptoms measure: Anxiety symptoms measure: Depression symptoms measure: Depression symptoms measure: Depression symptoms measure: Depression symptoms measure: Sleep diary: total sleep time measure: Sleep diary: total sleep time measure: Sleep diary: total sleep time measure: Sleep diary: total sleep time measure: Sleep diary: sleep onset latency measure: Sleep diary: sleep onset latency measure: Sleep diary: sleep onset latency measure: Sleep diary: sleep onset latency measure: Sleep diary: wake after sleep onset measure: Sleep diary: wake after sleep onset measure: Sleep diary: wake after sleep onset measure: Sleep diary: wake after sleep onset measure: Sleep diary: sleep efficiency measure: Sleep diary: sleep efficiency measure: Sleep diary: sleep efficiency measure: Sleep diary: sleep efficiency measure: Psychological flexibility measure: Psychological flexibility measure: Psychological flexibility measure: Psychological flexibility measure: Psychological inflexibility measure: Psychological inflexibility measure: Psychological inflexibility measure: Psychological inflexibility measure: Sleep-related arousal measure: Sleep-related arousal measure: Sleep-related arousal measure: Sleep-related arousal measure: Dysfunctional sleep-related cognitions measure: Dysfunctional sleep-related cognitions measure: Dysfunctional sleep-related cognitions measure: Dysfunctional sleep-related cognitions measure: Sleep-related safety behaviors measure: Sleep-related safety behaviors measure: Sleep-related safety behaviors measure: Sleep-related safety behaviors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Amsterdam city: Amsterdam state: Noord-Holland zip: 1018 WS country: Netherlands name: Mathilde I Looman, MSc role: CONTACT phone: (0)20 525 6810 phoneExt: +31 email: m.i.looman@uva.nl lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06336538 id: CASE1124 briefTitle: Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-01-31 date: 2025-01-31 date: 2024-03-28 date: 2024-03-29 name: Case Comprehensive Cancer Center class: OTHER briefSummary: The purpose of this research study is to develop and test an intervention designed to improve mood and reduce symptoms of depression. conditions: Breast Cancer conditions: Breast Cancer Female conditions: Breast Cancer Stage I conditions: Breast Cancer Stage II conditions: Breast Cancer Stage III conditions: Mild Depression conditions: Moderate Depression studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Investigator will first conduct focus groups with older (≥65 years old) African American/Black (AA/B) breast cancer survivors (BCS) with elevated depressive symptoms. They will collect participant perspectives on barriers and facilitators to participation in MBI clinical trials, as well as how to adapt this intervention, called Mindfulness-Based Cognitive Therapy-Brief (MBCT-Brief), to increase cultural relevancy for older AA/B BCS with elevated depressive symptoms. They will then conduct a single arm clinical trial that incorporates the results of the qualitative data analysis to establish feasibility and acceptability of MBCT-Brief. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 31 type: ESTIMATED name: MBCT measure: Mean participant attendance rate measure: Acceptability rate using CSQ(Client Satisfaction Questionnaire-8) measure: Change in fear of recurrence as assessed using FCRI(Fear of Cancer Recurrence Inventory) scores measure: Change in trait mindfulness as assessed using FFMQ-15(Five Facet of Mindfulness Scale Short Form) scores measure: Change in Quality of life as assessed using ICS-2(Impact of Cancer Scale version 2) scores measure: Change in depressive symptoms as assessed using PROMIS-D(Patient Reported Outcomes Measurement Information System-Depression) scores sex: FEMALE minimumAge: 65 Years stdAges: OLDER_ADULT facility: Cleveland Clinic Department of Wellness and Preventive Medicine city: Cleveland state: Ohio zip: 44106 country: United States name: Jacob Hill, ND role: CONTACT lat: 41.4995 lon: -81.69541 hasResults: False